SCYNEXIS, Inc., a biotechnology company developing medicines to overcome and prevent difficult-to-treat and drug-resistant infections, achieved a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment follows a development goal for the Phase 3 MARIO study for ibrexafungerp in invasive candidiasis.    The exclusive license agreement gives GSK rights to commercialize BREXAFEMME (ibrexafungerp tablets) for vulvov...